NCT04812782

Brief Summary

The purpose of this study is to evaluate the effects of the add-on of extra vergin olive oil or butter to a high glycemic index meal on endothelial function in subjects with type 1 Diabetes and healthy subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 12, 2018

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 16, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 16, 2019

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

March 12, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

March 24, 2021

Completed
Last Updated

March 24, 2021

Status Verified

March 1, 2021

Enrollment Period

1.7 years

First QC Date

March 12, 2021

Last Update Submit

March 20, 2021

Conditions

Keywords

Endothelial functionFMDgastric emptyingpost prandial glycemiadietary fatEVOObutter

Outcome Measures

Primary Outcomes (1)

  • Change of Endothelial function from pre meal to post meal period

    Flow mediated dilation technique by ultrasound

    before meal, 1 hour, 3 hour, 5 hour after meal

Secondary Outcomes (2)

  • Serum glucose

    before meal, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour after meal

  • Gastric emptying rate

    before meal, 15, 90, 120, 180, 240, 300 minutes after meal

Study Arms (2)

EVOO-Butter

EXPERIMENTAL

All patients and control subjects who met inclusion and exclusion criteria, and signed the Informed Consent, were scheduled for the two study visits, one week apart, during which each participant received two types of high GI meal: the first enriched with EVOO and the second with butter.

Dietary Supplement: EVOO supplementationDietary Supplement: Butter supplementation

Butter-EVOO

EXPERIMENTAL

All patients and control subjects who met inclusion and exclusion criteria, and signed the Informed Consent, were scheduled for the two study visits, one week apart, during which each participant received two types of high GI meal: the first enriched with Butter and the second with EVOO

Dietary Supplement: EVOO supplementationDietary Supplement: Butter supplementation

Interventions

EVOO supplementationDIETARY_SUPPLEMENT

We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with EVOO

Butter-EVOOEVOO-Butter
Butter supplementationDIETARY_SUPPLEMENT

We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with butter

Butter-EVOOEVOO-Butter

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age ≥ 18 years,
  • diagnosis of type 1 diabetes since at least 1 year,
  • HbA1c \<8.5% (69 mmol/mol),
  • stable insulin therapy for at least 3 months before the enrolment into the study

You may not qualify if:

  • pregnancy, celiac disease, history of cardiovascular diseases, hypertension, hyperlipidemia, retinopathy, nephropathy, neuropathy, and ongoing treatment with vasoactive drugs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Magna Graecia

Catanzaro, 88100, Italy

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Model Details: Cross-over, interventional, controlled study.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

March 12, 2021

First Posted

March 24, 2021

Study Start

February 12, 2018

Primary Completion

October 16, 2019

Study Completion

October 16, 2019

Last Updated

March 24, 2021

Record last verified: 2021-03

Locations